Google
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
NOVARTIS AG |
Delayed
Other stock markets
|
|
5-day change | 1st Jan Change | |
| 93.37 CHF | -0.53% | +0.94% | +11.70% | |
| Oct. 02 | Aura Biosciences Appoints New Chief Medical Officer | MT |
| Oct. 02 | Boehringer launches unbranded Humira biosimilar at 81% discount | RE |
Summary
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- Analyst opinion has improved significantly over the past four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- With an enterprise value anticipated at 3.78 times the sales for the current fiscal year, the company turns out to be overvalued.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector : Pharmaceuticals
| 1st Jan change | Capi. (M$) | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +11.70% | 212 B $ | B- | ||
| +83.43% | 1 229 M $ | - | ||
| -.--% | 90 M $ | - | - | |
| +141.94% | 1 689 M $ | - | - | |
| +3.12% | 70 M $ | - | ||
| +83.27% | 60 M $ | - | - | |
| -30.72% | 2 173 M $ | - | C | |
| +52.69% | 2 767 M $ | C- | ||
| -26.24% | 181 M $ | - | - | |
| +50.61% | 1 743 M $ | - | C |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
